Last reviewed · How we verify

NCT05453474

Cell-based Non-invasive Prenatal Testing as an Alternative to Invasive Chorionic Villus Sampling

Completed NA Last updated 31 January 2024
What this trial tests

NA trial testing Whole genome amplification in Hereditary Diseases in 48 participants. Completed in 27 June 2023.

Timeline
8 August 2021
Primary endpoint
27 June 2023
27 June 2023

Quick facts

Lead sponsorAalborg University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment48
Start date8 August 2021
Primary completion27 June 2023
Estimated completion27 June 2023
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Aalborg University Hospital

Who can join

Eligibility, female only, with Hereditary Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to evaluate cell-based non-invasive prenatal testing (cbNIPT) as an alternative to invasive chorionic villus sampling (CVS) in patients who achieve pregnancy following preimplantation genetic testing for hereditary disorders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hereditary Diseases

Currently open trials in the same condition.

Other Aalborg University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05453474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing